capecitabine
Showing 1 - 25 of 1,000
Breast Cancer Trial in Beijing (Mitoxantrone HCl liposome, Capecitabine)
Not yet recruiting
- Breast Cancer
- Mitoxantrone hydrochloride liposome
- Capecitabine
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Dec 1, 2023
Pancreas Cancer, Pancreas Adenocarcinoma Trial in Cleveland (Capecitabine)
Not yet recruiting
- Pancreas Cancer
- Pancreas Adenocarcinoma
- Capecitabine
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center, Seidman Cancer Ce
Oct 29, 2023
Triple Negative Breast Cancer, Residual Disease Trial (Tetrathiomolybdate, Capecitabine, Pembrolizumab)
Not yet recruiting
- Triple Negative Breast Cancer
- Residual Disease
- Tetrathiomolybdate
- +2 more
- (no location specified)
Nov 15, 2023
Gastrointestinal Cancer Trial (Capecitabine, Sacituzumab govetican)
Not yet recruiting
- Gastrointestinal Cancer
- Capecitabine
- Sacituzumab govetican
- (no location specified)
Oct 2, 2023
Recurrent Metastatic Nasopharyngeal Carcinoma Trial (Mitoxantrone HCl liposome injection, Capecitabine)
Not yet recruiting
- Recurrent Metastatic Nasopharyngeal Carcinoma
- Mitoxantrone hydrochloride liposome injection
- Capecitabine
- (no location specified)
Jan 29, 2023
Advanced Gastric Carcinoma Trial in Dhaka (Trastuzumab, Oxaliplatin, Capecitabine)
Completed
- Advanced Gastric Carcinoma
- Trastuzumab
- +2 more
-
Dhaka, BangladeshBangabandhu Sheikh Mujib Medical University
Aug 15, 2023
Metastatic Colorectal Cancer Trial in Guangzhou (Cetuximab, Capecitabine)
Recruiting
- Metastatic Colorectal Cancer
- Cetuximab
- Capecitabine
-
Guangzhou, Guangdong, ChinaThe Sixth Affiliated Hospital of Sun Yat-sen University
Mar 7, 2023
Breast, Metastatic, Triple Negative Trial in Gainesville, Jacksonville (Capecitabine, Sarilumab 150mg or 200 mg plus
Active, not recruiting
- Breast
- +4 more
- Capecitabine
- +2 more
-
Gainesville, Florida
- +1 more
Feb 2, 2023
HER2 Positive Metastatic Breast Cancer Trial in Beijing (pyrotinib, , Capecitabine)
Active, not recruiting
- HER2 Positive Metastatic Breast Cancer
- pyrotinib
- +2 more
-
Beijing, China307 Hospital Affiliated to Academy Military Medical Science
Oct 24, 2022
Hormone Receptor-positive Breast Cancer Trial in Tampa (Cemiplimab, Capecitabine)
Recruiting
- Hormone Receptor-positive Breast Cancer
- Cemiplimab
- Capecitabine
-
Tampa, FloridaMoffitt Cancer Center
Dec 30, 2022
Colorectal Cancer, Colorectal Cancer Stage IV Trial (Fruquintinib Plus Capecitabine, Capecitabine)
Not yet recruiting
- Colorectal Cancer
- Colorectal Cancer Stage IV
- Fruquintinib Plus Capecitabine
- Capecitabine
- (no location specified)
Jul 9, 2022
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer Trial in Australia, China
Recruiting
- Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
- LBL-007
- +3 more
-
Benowa, Queensland, Australia
- +7 more
Jan 30, 2023
Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct Trial run by the National Cancer Institute (NCI) (oxaliplatin,
Not yet recruiting
- Biliary Cancer
- +2 more
- oxaliplatin
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
May 13, 2023
Gastric Adenocarcinoma, Gastric Cancer, Esophagogastric Junction Trial run by the NCI (Paclitaxel, Capecitabine, BardPort
Recruiting
- Gastric Adenocarcinoma
- +3 more
- Paclitaxel
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 31, 2023
Breast Cancer Trial in Guangzhou (Capecitabine, Aromatase Inhibitor)
Active, not recruiting
- Breast Cancer
- Capecitabine
- Aromatase Inhibitor
-
Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Sun Yat-sen Uni
Jan 27, 2023
Breast Cancer Trial in Chicago (Cyclophosphamide, Methotrexate, Capecitabine)
Recruiting
- Breast Cancer
- Cyclophosphamide
- +2 more
-
Chicago, IllinoisUniversity of Illinois
Oct 18, 2023
Metastatic Breast Cancer Trial in Kansas City, Rochester, Saint Louis (ATI-2231, Capecitabine, Denosumab)
Not yet recruiting
- Metastatic Breast Cancer
- ATI-2231
- +3 more
-
Kansas City, Kansas
- +2 more
Mar 16, 2023
Triple Negative Breast Cancer Trial in Guangzhou (Capecitabine, Tucidinostat)
Recruiting
- Triple Negative Breast Cancer
- Capecitabine
- Tucidinostat
-
Guangzhou, Guangdong, ChinaSun-yat sen university cancer center
Nov 1, 2022
Colonic Tumors, Neoadjuvant Therapy, Immune Checkpoint Inhibitors Trial in Nanning (Tislelizumab, Oxaliplatin, Capecitabine)
Recruiting
- Colonic Neoplasms
- +2 more
- Tislelizumab
- +3 more
-
Nanning, Guangxi, ChinaThe First Affiliated Hospital of Guangxi Medical University
Nov 9, 2023
Recurrent Pituitary Adenomas Trial in New York (Capecitabine, Temozolomide)
Terminated
- Recurrent Pituitary Adenomas
- Capecitabine
- Temozolomide
-
New York, New YorkWeill Cornell Medical College
Jul 15, 2022
Cholangiocarcinoma, Intrahepatic Trial in Shanghai (Capecitabine, PD-1 Antibody(Tislelizumab))
Recruiting
- Cholangiocarcinoma, Intrahepatic
- Capecitabine
- PD-1 Antibody(Tislelizumab)
-
Shanghai, ChinaLulu@Huashan.Org.Cn
Aug 16, 2022
HER2-positive Breast Cancer, LMD Trial (Tucatinib 150 MG, Trastuzumab, Capecitabine)
Not yet recruiting
- HER2-positive Breast Cancer
- LMD
- Tucatinib 150 MG
- +3 more
- (no location specified)
Aug 24, 2023
Hematopoietic and Lymphoid System Tumor, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Tumor Trial (BET
Not yet recruiting
- Hematopoietic and Lymphoid System Neoplasm
- +5 more
- BET Bromodomain Inhibitor ZEN-3694
- +6 more
- (no location specified)
Apr 6, 2023
Capecitabine Versus S-1 as Adjuvant Therapy in Biliary Tract
Recruiting
- Biliary Tract Neoplasms
- +3 more
- S-1
- Capecitabine
-
Shanghai, ChinaHuashan hospital
Aug 16, 2022